Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

NCT04770220 is registered in ClinicalTrials.gov with Alzheon Inc. as lead sponsor.

NCT NCT04770220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04770220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Lead sponsor
Alzheon Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 19, 2021
Completion date
July 29, 2024
Enrollment
325 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

early alzheimer's disease